CareDx (CDNA) Jefferies Global Healthcare Conference 2025 summary

Leadership and Organizational Strengths

• Leadership team with deep experience from biotech and tech firms, supporting innovation and growth, with 650 employees globally, including 180 in commercial roles and 100–110 scientists focused on transplant care innovation.

• 80 software programmers dedicated to building digital solutions for transplant care and supporting efficiency for transplant centers.

Growth Strategy, Financial Performance, and Outlook

• Three primary growth drivers for 2025: new product launches, evidence generation for payer coverage, and operational excellence.

• Q1 2025 revenue reached $84.7 million, an 18% year-over-year increase, with testing volume up 12% to approximately 47,100, marking the seventh consecutive quarter of growth.

• Ended Q1 with $231M cash and no debt; completed $50M stock repurchase with an additional $50M authorized.

• 2025 revenue guidance: $365M–$375M; three-year target: $500M revenue, >70% gross margin, and 20% adjusted EBITDA margin by 2027.

• Three-year revenue CAGR target of 15% and incremental cash target of +$100M.

Market Landscape and Customer Adoption

• U.S. transplant market valued at $50B, with 46,000 annual transplants and $1M spent per organ.

• 70% of U.S. transplant centers use at least one software solution; ~200,000 HLA tests sold globally.

• Multi-solution accounts generate 2x testing services revenue and higher patient acquisition rates.

• 150,000 prescriptions filled annually for transplant patients.

• Market growth driven by technology innovation and government programs, especially in kidney transplantation.